Your browser doesn't support javascript.
loading
Dapagliflozin and Timing of Prior Heart Failure Hospitalization: A Patient-Level Meta-Analysis of DAPA-HF and DELIVER.
Butt, Jawad H; Jhund, Pardeep S; Docherty, Kieran F; Claggett, Brian L; Vaduganathan, Muthiah; Bachus, Erasmus; Hernandez, Adrian F; Lam, Carolyn S P; Inzucchi, Silvio E; Martinez, Felipe A; de Boer, Rudolf A; Kosiborod, Mikhail N; Desai, Akshay S; Køber, Lars; Ponikowski, Piotr; Sabatine, Marc S; Solomon, Scott D; McMurray, John J V.
Afiliação
  • Butt JH; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom; Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Jhund PS; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.
  • Docherty KF; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.
  • Claggett BL; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Vaduganathan M; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Bachus E; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R and D, AstraZeneca, Gothenburg, Sweden.
  • Hernandez AF; Duke University Medical Center, Durham, North Carolina, USA.
  • Lam CSP; National Heart Centre Singapore, Singapore.
  • Inzucchi SE; Duke-National University of Singapore, Singapore; Yale School of Medicine, New Haven, Connecticut, USA.
  • Martinez FA; University of Cordoba, Cordoba, Argentina.
  • de Boer RA; Erasmus Medical Center, Rotterdam, Netherlands.
  • Kosiborod MN; Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, Missouri, USA.
  • Desai AS; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Køber L; Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Ponikowski P; Department of Heart Disease, Wroclaw Medical University, Wroclaw, Poland.
  • Sabatine MS; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Solomon SD; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • McMurray JJV; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom. Electronic address: john.mcmurray@glasgow.ac.uk.
JACC Heart Fail ; 12(9): 1586-1599, 2024 Sep.
Article em En | MEDLINE | ID: mdl-38573262
ABSTRACT

BACKGROUND:

Patients recently hospitalized for heart failure (HF) are at a higher risk of adverse clinical outcomes, but they may experience a greater absolute and relative benefit from effective therapies than individuals who are considered more "stable."

OBJECTIVES:

The authors examined the effects of dapagliflozin according to the timing of prior HF hospitalization in a patient-level pooled analysis of DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) and DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure).

METHODS:

A total of 11,007 patients were randomized in DAPA-HF and DELIVER. The primary outcome was the composite of worsening HF or cardiovascular death.

RESULTS:

In total, 12.4% were hospitalized for HF within 3 months of randomization, 14.2% between 3 and 12 months, and 16.8% more than 1 year before randomization, whereas 56.5% had not been hospitalized. The risk of the primary endpoint was inversely associated with time from prior HF hospitalization, and patients with a recent HF hospitalization had the highest risk. Compared with placebo, dapagliflozin reduced the risk of the primary outcome across HF hospitalization category (0-3 months, HR 0.66 [95% CI 0.55-0.81]; 3-12 months, HR 0.73 [95% CI 0.59-0.90]; >1 year, HR 0.91 [95% CI 0.74-1.12]; and no prior hospitalization, HR 0.83 [95% CI 0.73-0.94]; Pinteraction = 0.09). The number of patients needed to treat with dapagliflozin to prevent 1 event over the median follow-up of 22 months was 13, 20, 23, and 28, respectively. The beneficial effect was consistent across the range of LVEF regardless of HF hospitalization category.

CONCLUSIONS:

The relative benefits of dapagliflozin were consistent across the range of LVEF regardless of the timing of the most recent HF hospitalization with a greater absolute benefit in patients with recent hospitalization.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos Benzidrílicos / Inibidores do Transportador 2 de Sódio-Glicose / Glucosídeos / Insuficiência Cardíaca / Hospitalização Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos Benzidrílicos / Inibidores do Transportador 2 de Sódio-Glicose / Glucosídeos / Insuficiência Cardíaca / Hospitalização Idioma: En Ano de publicação: 2024 Tipo de documento: Article